Journal ArticleDOI
Cardiac Resynchronization in Chronic Heart Failure
William T. Abraham,Westby G. Fisher,Andrew L. Smith,David B. Delurgio,Angel R. Leon,Evan Loh,Dusan Z. Kocovic,Milton Packer,Alfredo L. Clavell,David L. Hayes,Myrvin H. Ellestad,Robin J. Trupp,Jackie Underwood,Faith Pickering,Cindy Truex,Peggy McAtee,John C. Messenger +16 more
Reads0
Chats0
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.Abstract:
Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional clas...read more
Citations
More filters
Journal ArticleDOI
Mitral Regurgitation After Myocardial Infarction: A Review
TL;DR: Current medical options rely chiefly on angiotensin converting enzyme-inhibitors and beta-blocker therapy, and surgical approaches offer future promise, and both categories of therapeutic approaches should be evaluated by randomized controlled trials.
Journal ArticleDOI
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
William T. Abraham,Karl-Heinz Kuck,Rochelle L. Goldsmith,JoAnn Lindenfeld,Vivek Y. Reddy,Peter E. Carson,Douglas L. Mann,Benjamin Saville,Helen Parise,R. C. Chan,Phi Wiegn,Jeffrey L. Hastings,Andrew J. Kaplan,Frank T. Edelmann,Lars Lüthje,Rami Kahwash,Gery Tomassoni,David D. Gutterman,Angela Stagg,Daniel Burkhoff,Gerd Hasenfuß +20 more
TL;DR: CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations.
Journal ArticleDOI
Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation : The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry)
Maurizio Gasparini,Christophe Leclercq,Maurizio Lunati,Maurizio Landolina,Angelo Auricchio,Massimo Santini,Giuseppe Boriani,B. Lamp,Alessandro Proclemer,Antonio Curnis,Catherine Klersy,Francisco Leyva +11 more
TL;DR: Long-term survival after CRT among patients with AF+AVJA is similar to that observed among patients in SR, and Mortality is higher for AF patients treated with rate-slowing drugs.
Journal ArticleDOI
Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: New insights from continuous monitoring devices
TL;DR: Study of cardiovascular signals continuously sensed by implantable devices suggest that volume expansion, autonomic adaptation, and pulmonary interstitial edema begin several weeks before patients develop symptoms or demonstrate changes in daily weight.
Journal ArticleDOI
Variable left ventricular activation pattern in patients with heart failure and left bundle branch block
TL;DR: LV endocardial activation sequences in patients with chronic heart failure and LBBB are variable, which may have implications for patient selection for treatment with cardiac resynchronisation.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
Serge Cazeau,Christophe Leclercq,Thomas Lavergne,S Walker,Varma C,Cecilia Linde,Stéphane Garrigue,Lukas Kappenberger,G A Haywood,Massimo Santini,Bailleul C,Jean-Claude Daubert,Multisite Stimulation in Cardiomyopathies (Mustic) Study Investigators +12 more
TL;DR: In this article, transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle) were used to reduce ventricular asynchrony.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Journal ArticleDOI
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II Losartan Heart Failure Survival Study as discussed by the authors showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an ACE inhibitor.